Cargando…

New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic

Detalles Bibliográficos
Autor principal:	Seghatchian, Jerard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798433/ https://www.ncbi.nlm.nih.gov/pubmed/33461918 http://dx.doi.org/10.1016/j.transci.2021.103051

Ejemplares similares

WITHDRAWN: New Generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic
por: Seghatchian, J.
Publicado: (2021)

Facts and challenges on global deployment of vaccines for the immunotherapy of the evolving SARS Cov-2 variants: What a new year, with a fast spreading South African and the most fearful Brazilian variants, as the unwanted gifts, imposing enormous crises to surmount
por: Seghatchian, Jerard
Publicado: (2021)

Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic
por: Samad, Nandeeta, et al.
Publicado: (2020)

Editorial: Time to explore the missing links: from activated platelets and platelet extracellular vesicles in SARS-CoV-2 infection, through heterogeneity in the host physiological, immuno-inflammatory and haemostatic responses to mRNA-based vaccine or infection induced polyclonal neutralizing antibodies and passive immunity
por: Seghatchian, Jerard
Publicado: (2022)

Do highly transmissible omicron subtypes BA.4/BA.5 have any impact on the HLA class I /II antibodies of apheresis donors, and could mucosal omicron-specific vaccines prevent transmissibility and provide more durable protection?
por: Seghatchian, Jerard
Publicado: (2022)

Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
por: Lanza, Francesco, et al.
Publicado: (2021)

Ebola virus convalescent blood products: Where we are now and where we may need to go
por: Burnouf, Thierry, et al.
Publicado: (2014)

An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research
por: Putter, Jeffrey S., et al.
Publicado: (2020)

Spotlight on SARS CoV-2 infection inducing autoimmunity, through the formation of autoantibody to self hemostatic components or to host cells, often leading to severe thrombotic or bleeding events
por: Seghatchian, Jerard
Publicado: (2023)

Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron
por: Seghatchian, Jerard, et al.
Publicado: (2022)

“Go no Go” in plasma fractionation in the world's emerging economies: Still a question asked 70 years after the COHN process was developed!
por: Burnouf, Thierry, et al.
Publicado: (2014)

T-cell lymphocytopenia: An omnipresent predictor of morbidity and mortality in consequence of SARS-CoV disease and influenza A infections
por: Putter, Jeffrey S., et al.
Publicado: (2023)

Convalescent plasma: Would it prove to be magic potion/boon in the current scenario of COVID pandemic?
por: Pathak, Sangeeta
Publicado: (2020)

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

The secrets of human stem cell-derived transfusable RBC for targeted large-scale production and clinical applications: A fresh look into what we need most and lessons to be learned
por: Seghatchian, Jerard
Publicado: (2020)

In vitro mass production of reproducible human cells destined for substitution therapy: Challenges for development of functional materials for what we need most in transfusion!
por: Seghatchian, Jerard
Publicado: (2020)

Updates on Stem Cell Therapy in Transfusion Medicine, New Approaches to RBC Substitution Therapy, the Use of IFC for the Assessment of Extracellular- Derived Vesicles/Exosomes
por: Seghatchian, Jerard
Publicado: (2020)

Editorial: Time to explore the missing links: the cross-talk between COVID infection and cancer cells; lingering questions on the longitudinal efficacy of the front line immunotherapies against unpredictable “Omicron ghosts” and insights from CAR-T cell therapy pointing toward better clinical outcomes
por: Seghatchian, Jerard
Publicado: (2022)

Current Perspectives of convalescent plasma therapy in COVID-19
por: Sahu, Kamal Kant, et al.
Publicado: (2020)

Convalescent plasma for SARS-CoV-2 infection: win or learn
por: Contreras-Barbeta, Enric, et al.
Publicado: (2022)

The resurgence of convalescent plasma therapy
por: The Lancet Haematology
Publicado: (2020)

Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity
por: Lanza, Francesco, et al.
Publicado: (2020)

Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes
por: Amiral, Jean, et al.
Publicado: (2023)

Convalescent Plasma the Old Warhorse First to be Inducted in Pandemics is not the Zippy Chippy of Derby
por: Sachdev, Suchet, et al.
Publicado: (2021)

SARS-CoV-2 and cancer: the intriguing and informative cross-talk
por: Goubran, Hadi, et al.
Publicado: (2022)

Platelet and extracellular vesicles in COVID-19 infection and its vaccines
por: Goubran, Hadi, et al.
Publicado: (2022)

COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
por: Sullivan, David, et al.
Publicado: (2023)

Convalescent Plasma in COVID-19: To what Degree should Clinicians Rely on Currently Available Data?
por: Alhazzani, Waleed, et al.
Publicado: (2021)

Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike
por: Seghatchian, J., et al.
Publicado: (2020)

Cell culture – Fact and fiction
por: Smit Sibinga, Cees Th., et al.
Publicado: (2020)

Convalescent Plasma Transfusion for the Treatment of COVID-19 in Adults: A Global Perspective
por: Kanj, Saly, et al.
Publicado: (2021)

WITHDRAWN: Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike
por: Seghatchian, J., et al.
Publicado: (2020)

(A Little) Clarity on Convalescent Plasma for Covid-19
por: Katz, Louis M.
Publicado: (2021)

Convalescent Plasma for Covid-19 — Making Sense of the Inconsistencies
por: Estcourt, Lise, et al.
Publicado: (2022)

Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!
por: Seghatchian, Jerard, et al.
Publicado: (2020)

Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?
por: Amiral, Jean, et al.
Publicado: (2020)

Convalescent plasma for administration of passive antibodies against viral agents
por: Di Minno, Giovanni, et al.
Publicado: (2020)

COVID-19 convalescent plasma: current status, lessons from the past and future perspectives
por: Hervig, Tor Audun, et al.
Publicado: (2022)

The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy
por: Borlongan, Mia C., et al.
Publicado: (2020)

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
por: Focosi, D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ok9ns55o03l0ru5oi7bsddeqb